Gene Therapy Market Overview, Trends Forecast Analysis By Top Manufactures

 The global gene therapy market expected to reach USD 5.02 billion by 2028, according to a new study by Polaris Market Research. The report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

 

 

The market is fragmented based on the therapy area, vector type, approach, route of administration, and region. In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.

Based on the vector type, the industry is further bifurcated into viral and non-viral vectors. Based on the approach, the industry is further bifurcated into gene augmentation, oncolytic viral therapy, immunotherapy, and others. Based on the route of administration, the market is further bifurcated into intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal, and others.

 

Segment Highlights

• The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.
• Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.
• North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region
• The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020

 

List of Key Players

• Dimension Therapeutics
• Novartis AG
• Bluebird Bio
• Gilead Sciences Inc.
• Human Stem Cell Institute
• Spark Therapeutics
• Celgene Corporation
• Sangamo Biosciences
• GlaxoSmithKline
• Bristol Myer’s Squibb
• Celgene Corporation
• Others

Any Special Requirement | Speak to our Industry Expert : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

 

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region

 

Gene Therapy, Therapeutic Area Outlook (Revenue – USD Million, 2016 – 2028)

• Autoimmune Disorders
• Cardiovascular Diseases
• Dermatological Disorders
• Genetic Disorders
• Hematological Disorders
• Metabolic Disorders
• Muscle-related Diseases
• Oncological Disorders
• Ophthalmic Diseases
• Others

Gene Therapy, Vector Type Outlook (Revenue – USD Million, 2016 – 2028)

• Viral
  • Retroviral vectors
    • Gamma-retroviral vectors
    • Lentiviral vectors
  • Adeno-associated virus vectors
  • other viral vectors
• Non-viral
  • Oligonucleotides
  • Other non-viral vectors

Gene Therapy, Approach Outlook (Revenue – USD Million, 2016 – 2028)

• Augmentation
• Oncolytic Viral Therapy
• Immunotherapy
• Others

Gene Therapy, Route of Administration Outlook (Revenue – USD Million, 2016 – 2028)

• Intraarticular
• Intracerebellar
• Intradermal
• Intramuscular
• Intratumoral
• Intravenous
• Intravesical
• Intravitreal
• Subretinal
• Others

Gene Therapy Market With Business Strategies And Analysis To 2028

 Gene Therapy | 2021 Scope Of Current And Future Industry 

 

The global gene therapy market expected to reach USD 5.02 billion by 2028, according to a new study by Polaris Market Research. The report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

  

The market is fragmented based on the therapy area, vector type, approach, route of administration, and region. In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.

Based on the vector type, the industry is further bifurcated into viral and non-viral vectors. Based on the approach, the industry is further bifurcated into gene augmentation, oncolytic viral therapy, immunotherapy, and others. Based on the route of administration, the market is further bifurcated into intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal, and others.

 

Segment Highlights

• The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.
• Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.
• North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region
• The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020

 

List of Key Players

• Dimension Therapeutics
• Novartis AG
• Bluebird Bio
• Gilead Sciences Inc.
• Human Stem Cell Institute
• Spark Therapeutics
• Celgene Corporation
• Sangamo Biosciences
• GlaxoSmithKline
• Bristol Myer’s Squibb
• Celgene Corporation
• Others

Any Special Requirement | Speak to our Industry Expert : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

 

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region

 

Gene Therapy, Therapeutic Area Outlook (Revenue – USD Million, 2016 – 2028)

• Autoimmune Disorders
• Cardiovascular Diseases
• Dermatological Disorders
• Genetic Disorders
• Hematological Disorders
• Metabolic Disorders
• Muscle-related Diseases
• Oncological Disorders
• Ophthalmic Diseases
• Others

Gene Therapy, Vector Type Outlook (Revenue – USD Million, 2016 – 2028)

• Viral
  • Retroviral vectors
    • Gamma-retroviral vectors
    • Lentiviral vectors
  • Adeno-associated virus vectors
  • other viral vectors
• Non-viral
  • Oligonucleotides
  • Other non-viral vectors

Gene Therapy, Approach Outlook (Revenue – USD Million, 2016 – 2028)

• Augmentation
• Oncolytic Viral Therapy
• Immunotherapy
• Others

Gene Therapy, Route of Administration Outlook (Revenue – USD Million, 2016 – 2028)

• Intraarticular
• Intracerebellar
• Intradermal
• Intramuscular
• Intratumoral
• Intravenous
• Intravesical
• Intravitreal
• Subretinal
• Others

 

Gene Therapy Market Major Manufacturers and Production Price, Cost Revenue, Panel Glass Market Forecast 2026

 According to a new report published by Polaris Market Research, the global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need. Moreover, rising R&D spend on platform technologies by large and emerging biopharmaceutical companies and favorable regulatory environment will accelerate the clinical development and the commercial approval of gene therapies in the foreseeable future. Despite promise, the high cost of gene therapy represents a significant challenge for commercial adoption in the forecast period.

 

Gene therapy involves inactivating a mutated gene that is not functioning properly and introducing a new gene to assist in fighting a disease. Overall, the field of gene therapy continues to mature and advance with many products in development and nearing commercialization. For instance, Spark Therapeutics received approval of Luxturna, a rare form inherited blindness in December 2017. Gene therapy market in late 2017 also witnessed the approvals of Gilead/Kite Pharma’s Yescarta and Novartis’ Kymriah in the cancer therapeutic area.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

 

Gene therapy offers promise in the treatment of range of indications in cancer and genetic disorders. Large Pharmaceuticals and Biotechnology companies’ exhibit strong interest in this field and key among them include Allergan, Shire, Biomarin, Pfizer and GSK. The gene therapy space is witnessing a wave of partnerships and alliances. Pfizer has recently expanded its presence in gene therapy with the acquisition of Bamboo Therapeutics and Allergan entered the field, with the acquisition of RetroSense and its Phase I/II optogenetic program.

 

North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period.

 

Any Special Requirement | Speak to our Industry Expert : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

 

Key Findings from the study suggest products accessible in the market are much competitive and manufacturers are progressively concentrating on advancements to pick up an aggressive edge. Companies are in a stage of development of new items in order to guarantee simple implementation and connection with the current gene. The hospatility segment is anticipated to grow at a high growth rate over the forecast period with the expanding utilization of smart locks inferable from expanding security-related worries among clients amid their stay at the hotels. North America is presumed to dominate the global smart locks market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

 

Gene Therapy Market Business Growth, Development Factors and Growth Analysis 2020-2021

According to a new report published by Polaris Market Research, the global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need. Moreover, rising R&D spend on platform technologies by large and emerging biopharmaceutical companies and favorable regulatory environment will accelerate the clinical development and the commercial approval of gene therapies in the foreseeable future. Despite promise, the high cost of gene therapy represents a significant challenge for commercial adoption in the forecast period.

 

Gene therapy involves inactivating a mutated gene that is not functioning properly and introducing a new gene to assist in fighting a disease. Overall, the field of gene therapy continues to mature and advance with many products in development and nearing commercialization. For instance, Spark Therapeutics received approval of Luxturna, a rare form inherited blindness in December 2017. Gene therapy market in late 2017 also witnessed the approvals of Gilead/Kite Pharma’s Yescarta and Novartis’ Kymriah in the cancer therapeutic area.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

 

Gene therapy offers promise in the treatment of range of indications in cancer and genetic disorders. Large Pharmaceuticals and Biotechnology companies’ exhibit strong interest in this field and key among them include Allergan, Shire, Biomarin, Pfizer and GSK. The gene therapy space is witnessing a wave of partnerships and alliances. Pfizer has recently expanded its presence in gene therapy with the acquisition of Bamboo Therapeutics and Allergan entered the field, with the acquisition of RetroSense and its Phase I/II optogenetic program.

 

North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period.

 

Any Special Requirement | Speak to our Industry Expert : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

 

Key Findings from the study suggest products accessible in the market are much competitive and manufacturers are progressively concentrating on advancements to pick up an aggressive edge. Companies are in a stage of development of new items in order to guarantee simple implementation and connection with the current gene. The hospatility segment is anticipated to grow at a high growth rate over the forecast period with the expanding utilization of smart locks inferable from expanding security-related worries among clients amid their stay at the hotels. North America is presumed to dominate the global smart locks market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

 

Gene Therapy Market Size Historical Growth, Analysis, Opportunities and Forecast To 2021

 According to a new report published by Polaris Market Research, the global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need. Moreover, rising R&D spend on platform technologies by large and emerging biopharmaceutical companies and favorable regulatory environment will accelerate the clinical development and the commercial approval of gene therapies in the foreseeable future. Despite promise, the high cost of gene therapy represents a significant challenge for commercial adoption in the forecast period.

 

Gene therapy involves inactivating a mutated gene that is not functioning properly and introducing a new gene to assist in fighting a disease. Overall, the field of gene therapy continues to mature and advance with many products in development and nearing commercialization. For instance, Spark Therapeutics received approval of Luxturna, a rare form inherited blindness in December 2017. Gene therapy market in late 2017 also witnessed the approvals of Gilead/Kite Pharma’s Yescarta and Novartis’ Kymriah in the cancer therapeutic area.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

 

Gene therapy offers promise in the treatment of range of indications in cancer and genetic disorders. Large Pharmaceuticals and Biotechnology companies’ exhibit strong interest in this field and key among them include Allergan, Shire, Biomarin, Pfizer and GSK. The gene therapy space is witnessing a wave of partnerships and alliances. Pfizer has recently expanded its presence in gene therapy with the acquisition of Bamboo Therapeutics and Allergan entered the field, with the acquisition of RetroSense and its Phase I/II optogenetic program.

 

North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period.

 

Any Special Requirement | Speak to our Industry Expert : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

 

Key Findings from the study suggest products accessible in the market are much competitive and manufacturers are progressively concentrating on advancements to pick up an aggressive edge. Companies are in a stage of development of new items in order to guarantee simple implementation and connection with the current gene. The hospatility segment is anticipated to grow at a high growth rate over the forecast period with the expanding utilization of smart locks inferable from expanding security-related worries among clients amid their stay at the hotels. North America is presumed to dominate the global smart locks market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.